PPP1R15A and hepatocellular carcinoma: Through the above expression profiling analysis, the other phosphatase DUSP6 besides the PPP1R15A was also significantly increased in the combination-treated sorafenib-resistant HCC cells (SMMC7721 cells and PLC8024 cells), compared to the sorafenib alone-treated these cells (Fig. 5A).